Evidence map›Paper›PMID 40751186›Full record

ArticleBMC ophthalmology2025

Case of autosomal dominant optic atrophy with relatively good visual function.

Midori Tachibana, Takaaki Hayashi, Yuro Igawa, Kei Mizobuchi, Yosuke Miyasaka, Takashi Tsuchihashi, Kei Shinoda

Abstract readCase Reports
In one paragraph

Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Midori TachibanaDepartment of Ophthalmology, Faculty of Medicine, Saitama Medical University, 38 Moro-Hongo Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.
Takaaki HayashiDepartment of Ophthalmology, The Jikei University School of Medicine, 3-25-8, Nishishimbashi, Minato-ku, Tokyo, Japan.
Yuro IgawaDepartment of Ophthalmology, Faculty of Medicine, Saitama Medical University, 38 Moro-Hongo Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.
Kei MizobuchiDepartment of Ophthalmology, The Jikei University School of Medicine, 3-25-8, Nishishimbashi, Minato-ku, Tokyo, Japan.
Yosuke MiyasakaDepartment of Ophthalmology, Faculty of Medicine, Saitama Medical University, 38 Moro-Hongo Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.
Takashi TsuchihashiTsuchihashi Eye Clinic, 10-11 Nagatacho, Chichibu City, Saitama, 368-0013, Japan.
Kei ShinodaDepartment of Ophthalmology, Faculty of Medicine, Saitama Medical University, 38 Moro-Hongo Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan. shinok@saitama-med.ac.jp.

Funding

the Japan Society for the Promotion of Science (JSPS) 22K09838the Japan Society for the Promotion of Science (JSPS) 24K12771
6 · The paper itself

Abstract

backgroundDominant optic atrophy (DOA) is an inherited optic neuropathy caused by mutations of the OPA1 gene. Patients with DOA have a gradual loss of vision that is often detected in early life. While most cases stabilize at around a decimal best-corrected visual acuity (BCVA) of 0.1, some show mild impairments without visual field abnormalities. This then makes the diagnosis of DOA difficult. We report our longitudinal findings of a 56-year-old man with autosomal dominant DOA whose visual functions remained relatively good and genetic testing was needed for the diagnosis of DOA. CASE PRESENTATION: The patient was first examined 7 years earlier when he was 49-year-old at the Saitama Medical University Hospital. His major complaint was blurred vision. He had no medical or family history of ocular disorders, and his decimal BCVA was 1.0 (Snellen 20/20) in both eyes (OU). The intraocular pressure (IOP) was 13.7 mmHg in the right eye and 14.0 mmHg in the left eye. Slit-lamp examination revealed mild cataracts OU, and fundus examination showed temporal pallor of the optic discs OU. Humphrey visual field analyzer (HFA) standard 30 - 2 white-on-white perimetry indicated that the sensitivity was not reduced. Five years later, the patient returned for further examination because his vision had worsened. The decimal BCVA was 0.8 in the right eye and 0.6 in the left eye, and the IOP was within normal limits OU. The critical fusion frequency (CFF) was 30 Hz in the right eye and 31 Hz (normal values > 39 Hz) in the left eye. Slit-lamp examination and ophthalmoscopy showed no intraocular changes. Optical coherence tomography (OCT) showed a thinning of the retinal nerve fiber layer temporal to the optic disc. The contrast sensitivity was slightly decreased in both eyes, and the Panel D-15 color vision test was normal. Goldmann visual field testing with HFA SITA standard 10 - 2 and 24 - 2 white-on-white perimetry showed no obvious scotomas. However, HFA SITA standard 24 - 2 blue-on-yellow perimetry showed a diffuse decrease of sensitivity. Full-field and focal macular electroretinograms (ERGs) were normal in both eyes. Genetic testing was performed with the patient's consent, and next generation sequencing analysis identified a new heterozygous c.2331+2T>G variant in the OPA1 gene (NM_130837.3). At the final follow-up examination at age 55 years, the decimal BCVA was still relatively good at 0.8 in the right eye and 0.6 in the left eye.

conclusionsThese findings indicate that relatively good visual function can be maintained until the late middle age in patients with DOA, and genetic testing should be considered when circumpapillary RNFL thinning is observed, even in patients with relatively good visual acuity.

Indexed as

Optic Atrophy, Autosomal DominantVisual AcuityVisual FieldsElectroretinographyGTP PhosphohydrolasesHumansMaleMiddle AgedTomography, Optical CoherenceVisual Field TestsGTP PhosphohydrolasesOPA1 protein, humanDominant optic atrophyOptical coherence tomographyWhole exome analysis

Identifiers

PMID40751186
PMCPMC12315315

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.